noom microdose glp-1 introduces longevity-focused microdosing with at-home biomarker tracking Noom Launches GLP-1 Microdosing for
Description
Pfizer's withdrawal from the oral GLP-1 space leaves orforglipron without a near-term small-molecule competitor
A Claya Perspective So, how do you choose
About half of users stop GLP-1s shortly after treatment, due to the high cost of medications, uncomfortable side effects and age, researchers say
Well, the side effects is a very good point
Choosing a trusted provider is essential for ensuring the safety and effectiveness of your GLP-1 treatment
